All drugs are investigational and subject to regulatory approval. Phase 2a Topline Clinical Data October 2025 Nasdaq: SKYE © 2025 Skye Bioscience, Inc. 1 Disclaimer and Important Information for Investors This presentation ("Presentation") has been prepared solely for general information purposes by or on behalf of Skye Bioscience, Inc. (together with its subsidiaries and affiliates, "Skye"). Any discussion of the potential use or expected success of our product candidates is subject to our product candidat ...